Page 18 - Cipla
Cipla acquires brand, trademark for anti-diabetic drug Vysov in India
Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. However, it didn't disclose the acquisition amount. Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing. "Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said. The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said. Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 ..
 "Cipla acquires brand, trademark for anti-diabetic drug Vysov in India")
Domestic performance, steady growth outlook driving up Cipla stock
Promising domestic sales, new launches in the US are keeping analysts positive
 "Domestic performance, steady growth outlook driving up Cipla stock")
Cipla's Q2 profit before tax grows 34% on Indian business revival
Co undertook a distribution network restructuring exercise in the last few months
 "Cipla's Q2 profit before tax grows 34% on Indian business revival")
Cipla acquires anti-infective drug Elores from Venus Remedies
Elores is used to treat life threatening infections
Cipla looks at digital media for expanding footprint and reach customers
The pharma major looks to expand its footprint by driving up the diagnosis around diseases, uses digital media to take the brand directly to the end-user
 "Cipla looks at digital media for expanding footprint and reach customers")
Cipla rebounds 13% from 52-week low on heavy volumes
The United States Food and Drug Administration (USFDA) conducted a cGMP (current good manufacturing practices) inspection at the company's Goa manufacturing facility from September 16-27, 2019.
 "Cipla rebounds 13% from 52-week low on heavy volumes")
Cipla's unbranded drug business may take a hit in FY20, say analysts
Analysts see full recovery by Q3 as company revamps distribution network
Goa facility issue worsens Cipla's growth worries; stock falls over 3%
India business has been soft given the realignment of the sales channel
 "Goa facility issue worsens Cipla's growth worries; stock falls over 3%")
Cipla shareholders approve proposal to raise up to Rs 3,000 crore
In a regulatory filing, Cipla said 99.68% shareholders polled in favour of the resolution to raise funds
Declining India business pulls down Cipla's Q1 growth; US sales grow
Profitability though got a boost with higher contribution from limited competition products in the US
Cipla increases stake in consumer health biz to 100%, looks for tie-ups
The drug maker had set up a separate company with private equity investment in FY2016 to tap the fast growing over the counter medicine portfolio
 "Cipla increases stake in consumer health biz to 100%, looks for tie-ups")
Active pharmaceutical ingredients focus helps drug firms offset slowdown
Besides captive consumption, the company also supplies APIs to external customers across international markets
 "Active pharmaceutical ingredients focus helps drug firms offset slowdown")
As price pressure mounts, pharma companies tap analytics to cut costs
Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution
 "As price pressure mounts, pharma companies tap analytics to cut costs")
Cipla urges govt to increase funds, ease policies for domestic pharma firms
In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health
 "Cipla urges govt to increase funds, ease policies for domestic pharma firms")
InvaGen Pharma gets USFDA approval for neuropathic pain management drug
Cipla said the approved product is a generic therapeutic equivalent version of Pfizer's Lyrica
Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright
The JV will set up a manufacturing facility of respiratory products; the plant is expected to be commissioned in 2020
 "Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright")
Looking at continued growth across key markets in FY20, says Cipla
Total revenue from operations for the last fiscal stood at Rs 16,362.41 crore. It was Rs 15,219.25 crore in the preceding financial year
Street cautious on Cipla despite healthy March quarter numbers
Higher competitive intensity, increasing investments, and moderate growth could weigh on returns
US court denies Amgen's request for preliminary injunction against Cipla
Preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order
Margin gain remains a key trigger for Cipla, say analysts
Despite strong domestic growth and improving US prospects, analysts remain sceptical on improvement in profitability in the near-term
 "Margin gain remains a key trigger for Cipla, say analysts")
